Stuart Schreiber, Ph.D.

Stuart Schreiber is co-Founder of the Broad Institute, Howard Hughes Medical Institute Investigator, Morris Loeb Professor of Chemistry and Chemical Biology at Harvard University, and has been a member of the National Academy of Sciences since 1995.

His lab integrates chemical biology and human biology to advance the science of therapeutics. He is known for having developed systematic ways to explore biology, especially disease biology, using small molecules and for his role in the development of the field of chemical biology. Key advances include the discoveries of mTOR, histone deacetylases and evidence that chromatin marks regulate gene expression, and small molecules that promote protein–protein interactions. His research has been acknowledged through awards including most recently the Wolf Prize in Chemistry. His approach to therapeutics discovery guided the development of many biotechnology companies including Vertex Pharmaceuticals and Ariad Pharmaceuticals.

Read More
Ramnik Xavier, MD, Ph.D.

Ramnik Xavier is Chief of Gastroenterology at Massachusetts General Hospital (MGH), Kurt Isselbacher Professor of Medicine at Harvard Medical School, institute member of the Broad Institute of MIT and Harvard, and the director of MGH’s Center for the Study of Inflammatory Bowel Disease (IBD). As a clinical gastroenterologist and molecular biologist, he studies the specific molecular mechanisms involved in innate and adaptive immunity as well as the genetic variants associated with Crohn’s disease, ulcerative colitis, and autoimmunity. His laboratory uses genetic, structural, computational, and animal models, as well as clinical research to define the mechanisms controlling inflammation and immunity in vivo.

Read More
Charlie Albright

Charlie joined Editas Medicine as Chief Scientific Officer in August 2016. He brings more than 25 years of life sciences industry and academic leadership experience, most recently serving as vice president of genetically defined diseases and genomics at Bristol-Myers Squibb (BMS). Over his career, Charlie has led discovery programs that advanced investigational medicines into clinical development in a wide range of therapeutic areas, including neurodegeneration, pain, psychiatry, oncology and inflammation. Prior to his position as vice president of genetically defined diseases and genomics, he held multiple scientific leadership roles in neuroscience biology at BMS. Previously, he held positions at Incyte Corporation and DuPont Pharmaceuticals and was an assistant professor of biochemistry at Vanderbilt University. Charlie received a Bachelor of Science in Chemical Engineering and a Ph.D. in biology from the Massachusetts Institute of Technology (MIT). He was a postdoctoral fellow in the laboratory of Professor Robert Weinberg at the Whitehead Institute for Biomedical Research at MIT.

Read More
Amir Nashat, Ph.D.

Amir brings extensive company building experience to Jnana. He is a Managing Partner at Polaris Partners. In addition to serving as a Director and Chief Executive at Jnana, Amir currently represents Polaris as a Director of numerous companies including AgBiome, aTyr Pharmaceuticals (NASDAQ: LIFE), Marauder Therapeutics, Morphic Therapeutic, and Scholar Rock. He has served as a Director of Adnexus Therapeutics (Bristol Myers Squibb), Athenix Corporation (Bayer), Avila Therapeutics (Celgene), Living Proof (Unilever), Pervasis Therapeutics (Shire Pharmaceuticals), Receptos (Celgene), and Sun Catalytix (Lockheed Martin). At Living Proof, Sun Catalytix, and Olivo Labs Amir served as the company’s initial CEO. Amir also serves on the Partners Innovation Fund, the Investment Advisory Committee for The Engine at MIT, and helped launch the MIT Sandbox Innovation Fund. He has been named to the Forbes Midas List of “Top 100 Venture Capitalists.”

Prior to joining Polaris, Amir completed his PhD as a Hertz Fellow in Chemical Engineering at the Massachusetts Institute of Technology with a minor in Biology under the guidance of Dr. Robert Langer. Amir also earned both his MS and BS in Materials Science and Mechanical Engineering at the University of California, Berkeley. 

Read More
Joanne Kotz, Ph.D.

Joanne brings to Jnana broad life sciences experience in chemical biology and disease biology, operations, business and partnerships. Joanne came to Jnana from F-Prime, where she was assistant director of the F-Prime Biomedical Research Initiative, an effort focused on advancing the discovery of novel therapeutic treatments neurodegenerative diseases. Prior to this, Joanne was a director at the Broad Institute, where she was involved in creating and guiding project teams and partnerships to advance chemical probe and drug discovery efforts, including serving as alliance manager for the Broad-Bayer collaborations in oncology and cardiovascular disease.

Joanne received a PhD in chemistry from the University of California, Berkeley and conducted postdoctoral research at Genentech and the Necker Children’s Hospital in Paris. Before Broad, she was at Nature Publishing Group, first as a founding editor of the journal Nature Chemical Biology and later as a senior editor at the translational newsletter SciBX.

Read More
Joel Barrish, Ph.D.

Joel came to Jnana from Achillion Pharmaceuticals, where he served as CSO. Most of Joel’s career was spent as a medicinal chemist in pharma, where he capped a 28-year career at Bristol-Myers Squibb by spending the last 5 years as Vice President and Head of Discovery Chemistry, working across all therapeutic areas. During his BMS career, Joel worked with teams responsible for advancing more than 40 compounds into clinical development, including Sprycel (dasatinib), which he co-invented.  While at BMS, Joel and his colleagues made notable advances in the area of kinase inhibitor drug discovery, particularly in immunology and oncology. He is a co-author on over 130 peer reviewed publications and is a co-inventor on 40 issued U.S. patents.

Joel received a Ph.D. in Organic Chemistry from Columbia University working with Professor W. Clark Still. He spent 5 years at Hoffmann La-Roche prior to moving to BMS.

Read More